

**Cochrane** Database of Systematic Reviews

# Anticholinergics for urinary symptoms in multiple sclerosis (Review)

Nicholas RS, Friede T, Hollis S, Young CA

Nicholas RS, Friede T, Hollis S, Young CA. Anticholinergics for urinary symptoms in multiple sclerosis. *Cochrane Database of Systematic Reviews* 2015, Issue 6. Art. No.: CD004193. DOI: 10.1002/14651858.CD004193.pub3.

www.cochranelibrary.com

Anticholinergics for urinary symptoms in multiple sclerosis (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Trusted evidence. Informed decisions. Better health.

## TABLE OF CONTENTS

REASON FOR	WITHDRAWAL FROM PUBLICATION	 Ļ
WHAT'S NEW		 L



### [Intervention Review]

## Anticholinergics for urinary symptoms in multiple sclerosis

Richard S Nicholas<sup>1</sup>, Tim Friede<sup>2</sup>, Sally Hollis<sup>3</sup>, Carolyn A Young<sup>4</sup>

<sup>1</sup>West London Neurosciences Centre, Charing Cross Hospital, London, UK. <sup>2</sup>Abteilung fur Innere Medizin 1, Universitatsmedizin Göttingen, Göttingen, Germany. <sup>3</sup>c/o Cochrane Skin Group, University of Nottingham, Nottingham, UK. <sup>4</sup>The Walton Centre NHS Foundation Trust, Liverpool, UK

**Contact:** Richard S Nicholas, West London Neurosciences Centre, Charing Cross Hospital, Fulham Palace Road, London, W6 8RF, UK. richard.nicholas@btinternet.com.

**Editorial group:** Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group. **Publication status and date:** Withdrawn from publication for reasons stated in the review, published in Issue 6, 2015.

**Citation:** Nicholas RS, Friede T, Hollis S, Young CA. Anticholinergics for urinary symptoms in multiple sclerosis. *Cochrane Database of Systematic Reviews* 2015, Issue 6. Art. No.: CD004193. DOI: 10.1002/14651858.CD004193.pub3.

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## REASON FOR WITHDRAWAL FROM PUBLICATION

This review has been withdrawn for the following reasons:

- a review author contravenes Cochrane's Commercial Sponsorship Policy. This policy ensures the independence of Cochrane reviews by making sure that there is no bias associated with commercial conflicts of interest in the conduct of Cochrane reviews. The author was employed by the biopharmaceutical company AstraZeneca and cannot say with certainty that the company did not produce or have any financial interest in the interventions in this review

- the review is substantially out of date

To view the published versions of this article, please click the 'Other versions' tab.

The editorial group responsible for this previously published document have withdrawn it from publication.

#### WHAT'S NEW

Date	Event	Description
19 May 2008	Amended	Converted to new review format.